Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements

Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news